Bromocriptine Mesylate is Used for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It was first introduced by Esjay Pharma Llc in its drug Parlodel on Approved Prior to Jan 1, 1982. Another drug containing Bromocriptine Mesylate is Cycloset. 8 different companies have introduced drugs containing Bromocriptine Mesylate.

Bromocriptine Mesylate Patents

Given below is the list of patents protecting Bromocriptine Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Cycloset	US10688094	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US11000522	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US11666567	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US8431155	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US8613947	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US9192576	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US9522117	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US9700555	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US9993474	Bromocriptine formulations	Apr 30, 2032	Veroscience
Cycloset	US10688155	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun 07, 2030	Veroscience
Cycloset	US8877708	Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders	Jun 07, 2030	Veroscience
Cycloset	US9352025	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun 07, 2030	Veroscience
Cycloset	US9895422	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun 07, 2030	Veroscience
Cycloset	US7888310	Methods of identifying responders to dopamine agonist therapy	Jul 25, 2023 (Expired)	Veroscience
Cycloset	US8137992	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof	Jul 25, 2023 (Expired)	Veroscience
Cycloset	US8137993	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof	Jul 25, 2023 (Expired)	Veroscience
Cycloset	US8137994	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof	Jul 25, 2023 (Expired)	Veroscience
Cycloset	US5716957	Method for modifying and resetting the bloodstream prolactin levels of a human subject	Feb 10, 2015 (Expired)	Veroscience
Cycloset	US5679685	Accelerated release composition containing bromocriptine	Oct 21, 2014 (Expired)	Veroscience
Cycloset	US5468755	Therapeutic process for the treatment of the pathologies of Type II diabetes	Nov 21, 2012 (Expired)	Veroscience
Cycloset	US5756513	Therapeutic process for the treatment of the pathologies of type II diabetes	Nov 21, 2012 (Expired)	Veroscience
Cycloset	US5866584	Therapeutic process for the treatment of the pathologies of type II diabetes	Nov 21, 2012 (Expired)	Veroscience

Add above patents to watchlist

Bromocriptine Mesylate's Family Patents

Full family tree

Bromocriptine Mesylate Generic API Manufacturers

Several generic applications have been filed for Bromocriptine Mesylate. The first generic version for Bromocriptine Mesylate was by Sandoz Inc and was approved on Jan 13, 1998. And the latest generic version is by Padagis Us Llc and was approved on Oct 1, 2008.

Given below is the list of companies who have filed for Bromocriptine Mesylate generic, along with the locations of their manufacturing plants worldwide.